<?xml version='1.0' encoding='utf-8'?>
<document id="31871107"><sentence text="Association between Concomitant Use of Hydrochlorothiazide and Adverse Chemotherapy-Related Events among Older Women with Breast Cancer Treated with Cyclophosphamide."><entity charOffset="39-58" id="DDI-PubMed.31871107.s1.e0" text="Hydrochlorothiazide" /><entity charOffset="149-165" id="DDI-PubMed.31871107.s1.e1" text="Cyclophosphamide" /><pair ddi="false" e1="DDI-PubMed.31871107.s1.e0" e2="DDI-PubMed.31871107.s1.e0" /><pair ddi="false" e1="DDI-PubMed.31871107.s1.e0" e2="DDI-PubMed.31871107.s1.e1" /></sentence><sentence text="The pharmacy reference database, Micromedex, lists concomitant hydrochlorothiazide and cyclophosphamide use as a potential, major drug-drug interaction (DDI), although only one small, single-center study supports this claim"><entity charOffset="63-82" id="DDI-PubMed.31871107.s2.e0" text="hydrochlorothiazide" /><entity charOffset="87-103" id="DDI-PubMed.31871107.s2.e1" text="cyclophosphamide" /><pair ddi="false" e1="DDI-PubMed.31871107.s2.e0" e2="DDI-PubMed.31871107.s2.e0" /><pair ddi="false" e1="DDI-PubMed.31871107.s2.e0" e2="DDI-PubMed.31871107.s2.e1" /></sentence><sentence text=" Our objective was to estimate associations between this potential DDI and two adverse chemotherapy-related events, neutropenia-related hospitalizations and treatment regimen discontinuation, among a cohort of women with breast cancer initiating adjuvant chemotherapy containing cyclophosphamide"><entity charOffset="279-295" id="DDI-PubMed.31871107.s3.e0" text="cyclophosphamide" /></sentence><sentence text="" /><sentence text="Using linked Surveillance, Epidemiology, and End Results Program (SEER)-Medicare data, we included women 66 years and older with breast cancer diagnosis between 2007 and 2011, who initiated a regimen containing cyclophosphamide"><entity charOffset="211-227" id="DDI-PubMed.31871107.s5.e0" text="cyclophosphamide" /></sentence><sentence text=" Risk ratios (RR) and 95% confidence intervals for adverse outcomes comparing women exposed versus unexposed to the potential DDI were assessed using modified multivariable Poisson regression adjusting for potential confounders" /><sentence text="" /><sentence text="In total, 27% of women receiving cyclophosphamide treatment were exposed to concomitant hydrochlorothiazide, of which 11% experienced a neutropenia-related hospitalization and 21% discontinued their chemotherapy regimen prior to completion"><entity charOffset="33-49" id="DDI-PubMed.31871107.s8.e0" text="cyclophosphamide" /><entity charOffset="88-107" id="DDI-PubMed.31871107.s8.e1" text="hydrochlorothiazide" /><pair ddi="false" e1="DDI-PubMed.31871107.s8.e0" e2="DDI-PubMed.31871107.s8.e0" /><pair ddi="false" e1="DDI-PubMed.31871107.s8.e0" e2="DDI-PubMed.31871107.s8.e1" /></sentence><sentence text=" Adjusted risks of both adverse events were similar between those exposed and unexposed to the potential DDI [neutropenia-related hospitalization: adjusted RR (aRR) = 0" /><sentence text="92 (0" /><sentence text="70-1" /><sentence text="21); treatment discontinuation: aRR = 1" /><sentence text="00 (0" /><sentence text="96-1" /><sentence text="05)]" /><sentence text="" /><sentence text="Our results do not support an association between concomitant hydrochlorothiazide use and two clinically relevant adverse chemotherapy-related events"><entity charOffset="62-81" id="DDI-PubMed.31871107.s17.e0" text="hydrochlorothiazide" /></sentence><sentence text="" /><sentence text="Our results support reassessing and potentially lowering severity of this potential interaction in drug reference databases" /><sentence text="" /></document>